Page last updated: 2024-10-18

glycine and Lymphopenia

glycine has been researched along with Lymphopenia in 1 studies

Lymphopenia: Reduction in the number of lymphocytes.

Research Excerpts

ExcerptRelevanceReference
"Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18."2.77Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. ( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ma, WW1
Messersmith, WA1
Dy, GK1
Weekes, CD1
Whitworth, A1
Ren, C1
Maniar, M1
Wilhelm, F1
Eckhardt, SG1
Adjei, AA1
Jimeno, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors[NCT01125891]Phase 139 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for glycine and Lymphopenia

ArticleYear
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ce

2012